T. Rowe Price Associates, Inc. filed an amended Schedule 13G with the SEC on November 16, 2026, disclosing a 9.2% beneficial ownership position in Twist Bioscience Corp common stock as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: T. Rowe Price Associates, Inc. reported beneficial ownership of 6,084,637 shares of Twist Bioscience Corp common stock.
- Percent of class: The reported position represents 9.2% of the outstanding class of common stock.
- Sole voting power: T. Rowe Price disclosed sole voting power over 5,738,489 shares.
- Sole dispositive power: The filing attributes sole dispositive power over all 6,084,637 shares to T. Rowe Price, with no shared dispositive power reported.
- Event date: The date of the event requiring this filing is stated as September 30, 2026.
- Filer classification: T. Rowe Price Associates, Inc. is identified in the filing as an investment adviser (type "IA"), organized in Maryland.
T. Rowe Price Discloses Amended Ownership Position in Twist Bioscience
According to the filing, T. Rowe Price Associates, Inc., headquartered at 1307 Point Street, Baltimore, MD 21231, submitted Amendment No. 1 to its Schedule 13G regarding its holdings in Twist Bioscience Corp (NASDAQ:TWST), whose principal executive offices are listed at 681 Gateway Blvd., South San Francisco, CA, 94080. The filing covers common stock with CUSIP number 90184D100.
The filing reports that T. Rowe Price holds an aggregate of 6,084,637 shares beneficially owned, equating to 9.2% of the class. Of that total, the firm holds sole voting power over 5,738,489 shares and sole dispositive power over the full 6,084,637 shares. The filing records zero shared voting power and zero shared dispositive power.
In its certification, T. Rowe Price Associates, Inc. stated that "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing further states that T. Rowe Price "expressly denied" being the beneficial owner of the securities as a matter of legal construction under its Schedule 13G declaration. The document was signed by Ellen York, Vice President, on November 16, 2026.
What Was Disclosed
T. Rowe Price Associates, Inc. filed an amended Schedule 13G disclosing beneficial ownership of 6,084,637 shares, or 9.2%, of Twist Bioscience Corp common stock as of September 30, 2026, with sole dispositive power over all reported shares.



Please wait processing your request...